Navigation Links
Cytonus appoints Allergan executive Manisha Narasimhan, Ph.D. to its Board of Directors
Date:3/10/2020

Cytonus Therapeutics Inc. today announced that Manisha Narasimhan, Ph.D. has joined Cytonus’ Board of Directors. Dr. Narasimhan is Senior Vice President of Strategic Initiatives, Portfolio Innovation and Investor Relations at Allergan, plc.

“On behalf of the Board of Directors of Cytonus, we are extremely pleased to welcome Manisha Narasimhan as an independent director," commented Christopher Thorne, Chairman of the Board of Directors of Cytonus. "Her extensive pharmaceutical and biotechnology industry experience, combined with her scientific training and capital markets experience, make her a strong addition to our Board. We look forward to her future contributions on behalf of our shareholders."

Dr. Narasimhan was recently ranked #1 by Institutional Investor for Best Investor Relations Professional, Best IR Team, and Best IR Program in the pharmaceuticals sector, according to the 2020 All-America Executive Team rankings. She has wide-ranging expertise as a scientist, a financial executive and a highly effective communicator. Prior to joining Allergan, Dr. Narasimhan led the investor relations group at Regeneron Pharmaceuticals. She was previously an equity research analyst covering biotechnology at Canaccord Genuity and Piper Jaffray. Dr. Narasimhan began her career as a strategic management consultant for biotechnology and life science clients at Campbell Alliance. She received her Ph.D. in molecular biology from New York University.

About Cytonus Therapeutics Inc.

Cytonus Therapeutics Inc. is a San Diego based biotech company that has developed a vast platform of proprietary immunotherapeutic products to treat a wide range of medical conditions including cancers, infectious diseases, inflammatory diseases and cognitive disorders, and to improve patient outcomes. Its proprietary Cargocyte™ technologies are next-generation biomolecular delivery devices which have numerous medical applications across unmet therapeutic areas. Cargocytes™ are engineered to safely transport a multiplicity of therapeutic payloads into difficult-to-reach targeted tissues, and can be programmed to deliver selective, potent, and controllable "off-the-shelf" therapies. Cytonus' vast platform of therapeutics and vaccines has the potential to improve the health and lives of people with life-threatening conditions. For more information, we invite you to visit the Cytonus website at https://Cytonus.com. Please follow us on Cytonus on LinkedIn and on Twitter at: @CytonusTx.

Statements in this news release other than strictly historical facts, such as statements about Cytonus' plans and strategies, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for its products, are forward-looking statements. The words "believe," "expect," "aim," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. The company undertakes no obligation to publicly update or revise any forward-looking statement. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.

Join Cytonus on LinkedIn and follow its Twitter account at: @CytonusTx

Read the full story at https://www.prweb.com/releases/cytonus_appoints_allergan_executive_manisha_narasimhan_ph_d_to_its_board_of_directors/prweb16961253.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. Cytonus Therapeutics Announces Christopher Thorne as Chairman
2. Recognized industry leaders Richard Champlin, John Hood and Andrew Lowy join Cytonus’ Scientific Advisory Board
3. Cytonus, the US-based Biotech Platform Company, gains a boost from Strategic Partnership with Europe-based Phoenestra
4. Homeland Security Corporation (HSCC) Appoints New President with Biometrics and Access Control Solutions Expertise and Contacts
5. BioNano Genomics Appoints Dr. Fahim Amini As Vice President Commercial Operations EMEA
6. Techne Corporation Appoints Dr. J. Fernando Bazan As Chief Technology Officer
7. EyeLock Appoints Darlene Crumbaugh Vice President of Financial Services
8. EyeLock Appoints Michael Fiorito Vice President of Enterprise Accounts
9. EyeLock Appoints Roger An Vice President of Global Market Development
10. Profil Institute Appoints Dan Bradbury, former Amylin Pharmaceutical CEO, to Board of Directors
11. MedNet Appoints Clareece West As Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2020)... ... August 06, 2020 , ... Alucio™, ... to announce that Eric Chen and Jessica Wong have joined the company’s leadership ... Strategy, respectively. , Eric Chen heads development efforts for Alucio’s flagship product, Beacon, ...
(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received approval from the ... ProText™, making them the first Wharton’s jelly allografts to be assigned a Q code ... solutions are the first Wharton’s jelly allograft product to be recognized as a 361 ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... II contract awarded by the Joint Science & Technology Office—Chemical and Biological Defense ... to develop, optimize, and scale-up a highly efficient mammalian cell culture-based bioprocess suitable ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... Anomet Products has introduced ... materials for use with CRM, neurostimulation, vascular, and related devices. , Anomet ... design requirements, performance, and cost criteria; especially where solid wire is limited. Typical ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... industry, today announced the release of its signature product called Beacon - ... (MSLs) and other field medical professionals. , Beacon helps MSLs streamline ...
(Date:7/18/2020)... ... July 16, 2020 , ... Medial EarlySign ... detection and prevention of high-burden diseases, and Centric Consulting, a business and technology ... to utilize existing data in order to identify and prioritize patients for care. ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... is commonly used to suppress pigment formation in zebrafish embryos, maintaining optical transparency ... led by Dr MA has been using the zebrafish model to investigate the ...
Breaking Biology Technology: